Top

Published in:

01-07-2020 | Oral Cancer | Original Article

Identification of GIMAP7 and Rabl3 as Putative Biomarkers for Oral Squamous Cell Carcinoma Through Comparative Proteomic Approach

Authors: Muhammad Usman, Amber Ilyas, Zehra Hashim, Shamshad Zarina

Published in: Pathology & Oncology Research | Issue 3/2020

Abstract

Oral squamous cell carcinoma (OSCC) accounts for more than 90% of all oral cancers and has been listed as sixth most common human cancer. Due to late diagnosis and insufficient therapeutic response among patients, the survival rate remains very low accentuating the importance of early diagnostic markers. The study aimed to identify differentially expressed proteins in search for putative serum biomarkers and drug targets. Serum samples (n = 45) were depleted and resolved on two dimensional gel electrophoresis. Among differentially expressed proteins, two were identified using MALDI-TOF mass spectrometry. Gene expression levels of identified proteins were quantified in malignant and normal tissue using RT-qPCR. To validate serum Rabl3 expression, sandwich ELISA was performed. Proteomics analysis revealed two proteins which were found to be associated with oral cancer. The expression of GIMAP7 was found to be down regulated in serum of patients suffering from oral cancer while the expression of Rabl3 was found to be up-regulated. Gene expression analysis in malignant tissue and adjacent normal tissue revealed the same pattern. Quantitative ELISA was used to validate expression of Rabl3 in serum from oral cancer patients and healthy subjects which demonstrated significant up-regulation in cancer patients. Findings in current study demonstrate differential expression of novel putative biomarkers GIMAP7 and Rabl3 in oral cancer which suggests their potential role in oral cancer pathology and can be considered as predictive biomarkers.

Leemans CR, Braakhuis BJ, Brakenhoff RH (2011) The molecular biology of head and neck cancer. Nat Rev Cancer 11(1):9–22. https://doi.org/10.1038/nrc2982 CrossRefPubMed

Arantes LMRB, de Carvalho AC, Melendez ME, Carvalho AL, Goloni-Bertollo EM (2014) Methylation as a biomarker for head and neck cancer. Oral Oncol 50(6):587–592. https://doi.org/10.1016/j.oraloncology.2014.02.015 CrossRefPubMed

Tanaka T, Tanaka M, Tanaka T (2011) Oral carcinogenesis and oral cancer chemoprevention: a review. Pathol Res Int 2011:431246–431246. https://doi.org/10.4061/2011/431246 CrossRef

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492 CrossRefPubMed

Ali NS, Khuwaja AK, Ali T, Hameed R (2009) Smokeless tobacco use among adult patients who visited family practice clinics in Karachi, Pakistan. J Oral Pathol Med 38(5):416–421CrossRefPubMed

Johnson N (2001) Tobacco use and oral cancer: a global perspective. J Dent Educ 65(4):328–339CrossRefPubMed

Khan Z, Tönnies J, Müller S (2014) Smokeless tobacco and oral cancer in South Asia: a systematic review with meta-analysis. J Cancer Epidemiol 2014:394696–394696. https://doi.org/10.1155/2014/3946960 CrossRefPubMedPubMedCentral

Gigliotti J, Madathil S, Makhoul N (2019) Delays in oral cavity cancer. Int J Oral Maxillofac Surg. https://doi.org/10.1016/j.ijom.2019.02.015

Barbosa EB, Vidotto A, Polachini GM, Henrique T, Marqui AB, Tajara EH (2012) Proteomics: methodologies and applications to the study of human diseases. Rev Assoc Med Bras 58(3):366–375PubMed

10.

Turhani D, Krapfenbauer K, Thurnher D, Langen H, Fountoulakis M (2006) Identification of differentially expressed, tumor-associated proteins in oral squamous cell carcinoma by proteomic analysis. Electrophoresis 27(7):1417–1423. https://doi.org/10.1002/elps.200500510 CrossRefPubMed

11.

Malik UU, Zarina S, Pennington SR (2016) Oral squamous cell carcinoma: key clinical questions, biomarker discovery, and the role of proteomics. Arch Oral Biol 63:53–65. https://doi.org/10.1016/j.archoralbio.2015.11.017 CrossRefPubMed

12.

Blatt S, Kruger M, Ziebart T, Sagheb K, Schiegnitz E, Goetze E, Al-Nawas B, Pabst AM (2017) Biomarkers in diagnosis and therapy of oral squamous cell carcinoma: a review of the literature. J Craniomaxillofac Surg 45(5):722–730. https://doi.org/10.1016/j.jcms.2017.01.033 CrossRefPubMed

13.

Beretta L (2007) Proteomics from the clinical perspective: many hopes and much debate. Nat Methods 4(10):785–786. https://doi.org/10.1038/nmeth1007-785 CrossRefPubMed

14.

Fernández-Olavarría A, Mosquera-Pérez R, Díaz-Sánchez R-M, Serrera-Figallo M-A, Gutiérrez-Pérez J-L, Torres-Lagares D (2016) The role of serum biomarkers in the diagnosis and prognosis of oral cancer: a systematic review. J Clin Exp Dent 8(2):e184–e193. https://doi.org/10.4317/jced.52736 CrossRefPubMedPubMedCentral

15.

Ilyas A, Hashim Z, Zarina S (2015) Effects of 5'-azacytidine and alendronate on a hepatocellular carcinoma cell line: a proteomics perspective. Mol Cell Biochem 405(1-2):53–61. https://doi.org/10.1007/s11010-015-2395-1 CrossRefPubMed

16.

Musharraf SG, Hashmi N, Choudhary MI, Rizvi N, Usman A, Atta ur R (2012) Comparison of plasma from healthy nonsmokers, smokers, and lung cancer patients: pattern-based differentiation profiling of low molecular weight proteins and peptides by magnetic bead technology with MALDI-TOF MS. Biomarkers 17(3):223–230. https://doi.org/10.3109/1354750x.2012.657245 CrossRefPubMed

17.

Bhurgri Y (2005) Cancer of the oral cavity - trends in Karachi South (1995-2002). Asian Pac J Cancer Prev 6(1):22–26PubMed

18.

Chen Y, Azman SN, Kerishnan JP, Zain RB, Chen YN, Wong YL, Gopinath SC (2014) Identification of host-immune response protein candidates in the sera of human oral squamous cell carcinoma patients. PLoS One 9(10):e109012. https://doi.org/10.1371/journal.pone.0109012 CrossRefPubMedPubMedCentral

19.

Nitta T, Nasreen M, Seike T, Goji A, Ohigashi I, Miyazaki T, Ohta T, Kanno M, Takahama Y (2006) IAN family critically regulates survival and development of T lymphocytes. PLoS Biol 4(4):e103. https://doi.org/10.1371/journal.pbio.0040103 CrossRefPubMedPubMedCentral

20.

Poirier GM, Anderson G, Huvar A, Wagaman PC, Shuttleworth J, Jenkinson E, Jackson MR, Peterson PA, Erlander MG (1999) Immune-associated nucleotide-1 (IAN-1) is a thymic selection marker and defines a novel gene family conserved in plants. J Immunol 163(9):4960–4969PubMed

21.

Pandarpurkar M, Wilson-Fritch L, Corvera S, Markholst H, Hornum L, Greiner DL, Mordes JP, Rossini AA, Bortell R (2003) Ian4 is required for mitochondrial integrity and T cell survival. Proc Natl Acad Sci U S A 100(18):10382–10387. https://doi.org/10.1073/pnas.1832170100 CrossRefPubMedPubMedCentral

22.

Schnell S, Demolliere C, van den Berk P, Jacobs H (2006) Gimap4 accelerates T-cell death. Blood 108(2):591–599. https://doi.org/10.1182/blood-2005-11-4616 CrossRefPubMed

23.

Shiao YM, Chang YH, Liu YM, Li JC, Su JS, Liu KJ, Liu YF, Lin MW, Tsai SF (2008) Dysregulation of GIMAP genes in non-small cell lung cancer. Lung Cancer 62(3):287–294. https://doi.org/10.1016/j.lungcan.2008.03.021 CrossRefPubMed

24.

Huang Z, Zhang W, Gao C, Ji B, Chi X, Zheng W, Wang HL (2016) Dysregulation of GTPase IMAP family members in hepatocellular cancer. Mol Med Rep 14(5):4119–4123. https://doi.org/10.3892/mmr.2016.5764 CrossRefPubMedPubMedCentral

25.

Colicelli J (2004) Human RAS superfamily proteins and related GTPases. Sci STKE 2004(250):Re13. https://doi.org/10.1126/stke.2502004re13 CrossRefPubMedPubMedCentral

26.

Agarwal R, Jurisica I, Mills GB, Cheng KW (2009) The emerging role of the RAB25 small GTPase in cancer. Traffic (Copenhagen, Denmark) 10(11):1561–1568. https://doi.org/10.1111/j.1600-0854.2009.00969.x CrossRef

27.

Li Q, Wang L, Zeng L, Zhang Y, Li K, Jin P, Su B, Wang L (2010) Evaluation of the novel gene Rabl3 in the regulation of proliferation and motility in human cancer cells. Oncol Rep 24(2):433–440PubMed

28.

Zhang W, Sun J, Luo J (2016) High expression of Rab-like 3 (Rabl3) is associated with poor survival of patients with non-small cell lung cancer via repression of MAPK8/9/10-Mediated autophagy. Med Sci Monit 22:1582–1588. https://doi.org/10.12659/MSM.898632 CrossRefPubMedPubMedCentral

29.

Pan Y, Liu Z, Feng Z, Hui D, Huang X, Tong D, Jin Y (2017) The overexpression of Rabl3 is associated with pathogenesis and clinicopathologic variables in hepatocellular carcinoma. Tumour Biol 39(4):1010428317696230. https://doi.org/10.1177/1010428317696230 CrossRefPubMed

30.

An J, Liu Z, Liang Q, Pan Y, Li H, Wang R, Jin Y (2017) Overexpression of Rabl3 and Cullin7 is associated with pathogenesis and poor prognosis in hepatocellular carcinoma. Hum Pathol 67:146–151. https://doi.org/10.1016/j.humpath.2017.07.008 CrossRefPubMed

Title: Identification of GIMAP7 and Rabl3 as Putative Biomarkers for Oral Squamous Cell Carcinoma Through Comparative Proteomic Approach
Authors: Muhammad Usman
Amber Ilyas
Zehra Hashim
Shamshad Zarina
Publication date: 01-07-2020
Publisher: Springer Netherlands
Keywords: Oral Cancer
Oral Cavity Carcinoma
Biomarkers
Published in: Pathology & Oncology Research / Issue 3/2020
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-019-00775-1

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Image Credits

ASCO 2024 | Highlights of the Day: Breast cancer – metastatic/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Gynecologic Cancer/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Breast Cancer – local/regional/adjuvant/© 2024 American Society of Clinical Oncology, all rights reserved., Melanoma/© selvanegra / Getty Images / iStock, Antibody drug conjugated with cytotoxic payload/© Love Employee / Getty images / iStock

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2020

Primary and Secondary Breast Lymphoma: Focus on Epidemiology and Imaging Features

Polymorphisms in XPC Gene and Risk of Uterine Leiomyoma in Reproductive Women

Association between MICA rs2596542 Polymorphism with the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients

Comprehensive Analysis of Aberrantly Expressed Profiles of lncRNAs and miRNAs with Associated ceRNA Network in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma

Comparative Application of Different Substaging Techniques for Non-Muscle Invasive Urothelial Carcinoma

Correction to: BRCA1 and BRCA2 Germline Mutation Analysis in Hereditary Breast/Ovarian Cancer Families from the Aures Region (Eastern Algeria): First Report